Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis -- Ignore unavailable to you. Want to Upgrade?

To: Clarksterh who wrote (1363)	1/26/1998 3:51:00 PM
From: Robert Busse	Read Replies (1) \| Respond to of 1693

It won't be - I talked to Qdel today and was told that their flu test is right on target and Glaxo is very happy with their progress - They always intended to "time" their test to coincide w/ Glaxo's approval of Zanamivir - I was also told that BioStar/Biota test is 15 minutes vs Qdel's anticipated 5 minutes. By way of background, Biota of Australia actually developed Zanamivir, or GG167, a neuraminidase inhibitor for tx of flu, and licensed it to Glaxo for testing, manufacturing and worldwide distribution. When Glaxo wanted a diagnostic test to go with it, they talked to both Biota and Quidel - Glaxo not only chose Qdel to make the test, they also agreed to pay all of Qdel's R + D costs associated therewith - this is a real vote of confidence for Qdel in my opinion. It is also Qdel's plan to seek a CLIA waiver for their product - I don't think BioStar's current product would qualify for a CLIA waiver because of the 15 minute wait.